Introduction The multiple sclerosis (MS) therapeutic landscape is undergoing a structural shift driven by next-generation neuroimmunology. Among the most promising advances is the emergence of Bruton’s tyrosine kinase (BTK) inhibitors—a novel class of oral, brain-penetrant therapies designed to target both peripheral and central nervous system inflammation. Unlike traditional...